NASDAQ
12.34USD
+0.23 (+1.90%)
Dots are scored news catalysts — size = impact, color = sentiment. Tap one to read it.
Market cap
211.1M
P/E
—
EPS
—
Beta
0.37
52W range
11.13-16.77
Day range
12.14–12.48
Open
12.20
Prev close
12.11
Volume
103.3K
Avg volume
201.6K
Dividend
0.00
IPO
2026-02-27
https://www.prnewswire.com/news-releases/atrium-therapeutics-announces-fda-clearance-of-investigational-new-drug-application-for-atr-1072-for-treatment-of-prkag2-syndrome-302824844.html · 7/14/2026+0.80
https://seekingalpha.com/article/4920275-novartis-pipeline-building-continues-pelacarsen-readout-coming-soon · 7/7/2026+0.60
https://www.benzinga.com/trading-ideas/long-ideas/26/04/51932465/top-3-health-care-stocks-that-could-lead-to-your-biggest-gains-this-month · 4/21/2026+0.60
https://www.prnewswire.com/news-releases/hareholder-alert-the-ma-class-action-firm-continues-to-investigate-the-mergertbhc-rna-new-and-two-302675504.html · 1/31/2026-0.50
https://www.zacks.com/stock/news/2795595/sarepta-s-stock-rises-on-positive-updates-on-dm1-therapy?cid=CS-STOCKNEWSAPI-FT-analyst_blog|company_news_medical_sector-2795595 · 11/25/2025-0.40
https://www.globenewswire.com/news-release/2025/11/22/3193088/0/en/Halper-Sadeh-LLC-Encourages-WTRG-RNA-TCBX-Shareholders-to-Contact-the-Firm-to-Discuss-Their-Rights.html · 11/22/2025-0.20
https://www.investopedia.com/why-avidity-biosciences-and-dyne-therapeutics-stocks-soared-monday-11837362 · 10/27/2025+1.00
https://seekingalpha.com/article/4833603-wall-street-breakfast-podcast-novartis-puts-12b-on-the-table · 10/27/2025+1.00
https://www.prnewswire.com/news-releases/avidity-biosciences-enters-into-agreement-to-be-acquired-by-novartis-ag-302594703.html · 10/26/2025+1.00
https://www.globenewswire.com/news-release/2025/10/26/3174251/0/en/Novartis-agrees-to-acquire-Avidity-Biosciences-an-innovator-in-RNA-therapeutics-strengthening-its-late-stage-neuroscience-pipeline.html · 10/26/2025+1.00
Atrium Therapeutics, Inc. is a biopharmaceutical company dedicated to revolutionizing the treatment of cardiomyopathies by delivering innovative ribonucleic acid (RNA) therapeutics directly to the heart. Their development-stage portfolio currently includes ATR 1072, a siRNA-based therapy targeting the PRKAG2 gene for the treatment of PRKAG2 syndrome, and ATR 1086, another siRNA therapy aimed at the PLN gene to address PLN cardiomyopathy. The company is also actively developing a wider range of pipeline candidates designed to combat various genetic and cardiac diseases. Founded in 2025, Atrium Therapeutics is based in San Diego, California.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
